Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.9K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

16.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
16.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

769
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The last post.

Journal of thrombosis and haemostasis : JTH·2018
Same author

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.

Journal of thrombosis and haemostasis : JTH·2018
Same author

More kudos.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Ranking the stars.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Predators.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Summertime.

Journal of thrombosis and haemostasis : JTH·2018

Related Experiment Video

Updated: Apr 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.6K

Genetics in thrombophilia. An update.

P H Reitsma1

  • 1Pieter H. Reitsma, Department of Thrombosis and Haemostasis Einthoven Laboratory for Experimental Vascular Medicine, C7Q-14g Leiden University Medical Center Leiden, the Netherlands,

Hamostaseologie
|December 4, 2014
PubMed
Summary

Understanding inherited risk factors for venous thromboembolism (VTE) is crucial for prevention. While genetic testing isn't likely for primary VTE prevention, genetic risk scores may help stratify recurrence risk in patients.

Keywords:
Venous thrombosisgeneticsmutationsthrombophilia

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

148
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:54

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

351

Related Experiment Videos

Last Updated: Apr 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.6K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

148
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:54

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

351

Area of Science:

  • Medical Genetics
  • Hematology
  • Public Health

Background:

  • Venous thromboembolism (VTE) is a significant global health issue with high incidence and mortality rates.
  • Despite advances in understanding inherited VTE risk, its application in disease prevention remains challenging.
  • VTE recurrence affects a substantial portion of surviving patients, highlighting the need for effective prevention strategies.

Purpose of the Study:

  • To explore the role of inherited risk factors in the primary and secondary prevention of venous thromboembolism.
  • To evaluate the potential utility of genetic testing and risk scores in managing VTE.
  • To assess the current understanding and future directions in leveraging genetic knowledge for VTE prevention.

Main Methods:

  • Review of current scientific literature on inherited VTE risk factors.
  • Analysis of the impact of genetic variations on VTE incidence and recurrence.
  • Evaluation of the clinical applicability of genetic risk stratification tools.

Main Results:

  • Genetic testing is unlikely to be a primary prevention tool for VTE.
  • Individual genetic variations have smaller effect sizes for recurrence compared to first VTE events.
  • Multilocus genetic risk scores show promise in classifying VTE recurrence risk.

Conclusions:

  • Inherited VTE risk factors are complex and their application in prevention requires further research.
  • Genetic risk scores can stratify patients into high and low recurrence risk subgroups.
  • The use of genetic information to tailor VTE treatment intensity and duration requires further investigation.